Complement C4A/C4B antibody

Details for Product No. ABIN111802
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms C4, C4-1, C4b
Reactivity
Human
(26), (1), (1), (1), (1)
Host
Mouse
(15), (8), (2), (1), (1)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(1)
Application
Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA), Immunofluorescence (IF), Immunohistochemistry (Frozen Paraffin-embedded Sections) (IHC (frpe)), Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
(12), (9), (8), (6), (5), (4), (3), (2), (2), (1), (1), (1)
Pubmed 7 references available
Quantity 0.1 mg
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN111802
1,039.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Native human C4 from plasma
Clone 10-11-14
Isotype IgG1
Specificity This antibody recognises the secreted protein complement component 4d (C4d). C4d was accepted in 2003 into the Banff classification for identification of acute AMR (Racusen et al. 2003). Mouse anti Human C4d antibody, clone 10-11 is specific for C4d, a marker that can be used in the detection of acute AMR for kidney, heart, pancreas and lung allografts. C4d is regarded as a key marker of antibody-mediated cell injury and humoral rejection (Sacks and Chowdhury 2002). Complement 1 complex cleaves complement 4 (C4) to form C4b and C4a. C4b levels are strictly regulated. Single site cleavage of the C4b's alpha chain by Factor I forms iC4b and blocks C3 convertase, inhibiting opsonization and activation of the classical pathway. This requires C4 binding protein or CR1 as a cofactor. iC4b is further degraded into C4d and C4c. C4b's short half life means that C4d is present in serum at high enough concentrations to make it a useful marker for classical complement activation (Collins et al. 1999). Mouse anti Human C4d antibody, clone 10-11 is used to detect the biomarker C4d which has been described as a
Purification Affinity chromatography on Protein A.
Background The complement 1 complex cleaves complement 4 (C4) to form C4b and C4a. C4b levels are strictly regulated. Single site cleavage of the C4bs alpha chain by Factor I forms iC4b and blocks C3 convertase, inhibiting opsonisation and activation of the classical pathway. This requires C4 binding protein or CR1 as a cofactor. iC4b is further degraded into C4d and C4c. C4ds short half life means that C4d is present in serum at high enough concentrations to make it a useful marker for classical complement activation. C4 has been linked to susceptibility to systemic lupus erythematosous.Synonyms: Acidic complement C4, Basic complement C4, CPAMD2, CPAMD3, Complement component 4
Gene ID 720
NCBI Accession NP_009224
UniProt P0C0L4
Application Notes Immunohistochemistry on Frozen Sections (1/100-1/750): works very well on acetone-fixed,frozen renal biopsies, Strong staining is observed in the glomeruli and in some cases theperitubular capillaries. Immunohistochemistry on Paraffin Sections: variable result on formalin-fixed,paraffin-embedded sections, It has been observed that pre-treatment with 88 % formic acidfor 20 minutes at room temperature is beneficial. ELISA (1/5000-1/20000). Western Blot. Immunofluorescence (1/250-1/600).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Concentration 1.0 mg/mL
Buffer Borate buffered saline, 0.09 % Sodium Azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Background publications Rogers, Cooper, Webster et al.: "Complement activation by beta-amyloid in Alzheimer disease." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, Issue 21, pp. 10016-20, 1992 (PubMed).

Collins, Schneeberger, Pascual et al.: "Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries." in: Journal of the American Society of Nephrology : JASN, Vol. 10, Issue 10, pp. 2208-14, 1999 (PubMed).

Stoltzner, Grenfell, Mori et al.: "Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease." in: The American journal of pathology, Vol. 156, Issue 2, pp. 489-99, 2000 (PubMed).

Mauiyyedi, Pelle, Saidman et al.: "Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries." in: Journal of the American Society of Nephrology : JASN, Vol. 12, Issue 3, pp. 574-82, 2001 (PubMed).

Mauiyyedi, Crespo, Collins et al.: "Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification." in: Journal of the American Society of Nephrology : JASN, Vol. 13, Issue 3, pp. 779-87, 2002 (PubMed).

Knechtle, Pirsch, H Fechner et al.: "Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study." in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Vol. 3, Issue 6, pp. 722-30, 2003 (PubMed).

Xu, Melle, Golemanov et al.: "Shape and buckling transitions in solid-stabilized drops." in: Langmuir : the ACS journal of surfaces and colloids, Vol. 21, Issue 22, pp. 10016-20, 2005 (PubMed).

Validation Images
Did you look for something else?
back to top